Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Dry Eye > Age, gender, and gland health tied to IPL results in dry eye treatment
  • Dry Eye

Age, gender, and gland health tied to IPL results in dry eye treatment

Kelsey Moroz

Certain factors are associated with poorer outcomes in patients undergoing intense pulsed light (IPL) therapy for dry eye disease (DED), according to a study.

The analysis included 63 eyes, divided into groups based on their post-treatment improvement in DED signs and symptoms.

There were significant improvements in fluorescein staining and Schirmer II test results after IPL treatment (both P < 0.05), but symptoms overall showed no significant change (P = 0.834). Risk factors associated with poor outcomes included advanced age, female sex, prior refractive surgery, lower noninvasive tear break-up time, and greater meibomian gland loss (all P < 0.05).

Women and those with prior refractive surgery were more likely to experience minimal symptom improvement, while older age, reduced pretreatment noninvasive tear break-up time, and higher rates of gland loss correlated with poor improvement in clinical signs.

Reference
Lee CY, Yang SF, Chen HC, et al. Predisposing factors for poor outcomes after intense pulsed light treatment for dry eye disease: A retrospective case-control study. Int J Med Sci. 2024;21(15):2919-2925. doi: 10.7150/ijms.101341. PMID: 39628696; PMCID: PMC11610335.

Share

Related Content

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

  • Conference Roundup

Ocular staining and dry mouth may help identify Sjögren’s-related dry eye

  • Conference Roundup

Daily vaping associated with increased risk of ocular surface disease

  • Conference Roundup

Nearly half of eye care providers show Demodex infestation, with severity increasing over time in practice

  • Conference Roundup

Higher Demodex burden linked to reduced lipid layer thickness in blepharitis

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon